药剂师参与院内复苏或医疗应急响应事件的影响:系统评价
该系统评价按PRISMA指南检索1995年1月至2023年4月文献,旨在评估医院内需复苏或医疗应急响应团队救治的危重患者中,药剂师在场对用药及患者结局的影响。共纳入30项研究(29项队列研究、1项随机对照试验),覆盖急性卒中、心脏骤停、快速响应呼叫、ST段抬高型心肌梗死、急性出血、严重创伤复苏、脓毒症和癫痫持续状态8个患者队列。最常报告且23项研究显示有统计学显著获益的结局是用药至给药时间;较少研究报告死亡率等患者结局的显著差异,仅8项研究评为低偏倚风险。结论支持药剂师参与可改善时间关键性药物启动时间、用药适宜性和指南依从性,但研究多为小型回顾性,不足以检测住院时长和死亡率差异,未来需在急诊复苏场景开展对照、前瞻性研究。
要点
- 纳入30项研究(29项队列、1项随机对照试验),覆盖急性卒中、心脏骤停、快速响应呼叫、ST段抬高型心肌梗死、急性出血、严重创伤复苏、脓毒症和癫痫持续状态8个队列。
- 最常报告的结局是用药至给药时间,23项研究显示有统计学显著获益。
- 较少研究报告死亡率等患者结局指标的显著差异。
- 仅8/30项研究评为低偏倚风险,研究多为小型回顾性,不足以检测住院时长和死亡率差异。
- 作者认为结果支持药剂师在场和干预对复苏或医疗应急响应救治具有有益影响,未来需在急诊复苏场景开展对照、前瞻性研究。
适用人群与场景
- 医院内需复苏或医疗应急响应团队救治的危重住院患者。
- 研究覆盖急性卒中、心脏骤停、快速响应呼叫、ST段抬高型心肌梗死、急性出血、严重创伤复苏、脓毒症和癫痫持续状态8个患者队列。
研究设计与关键结果
- 系统评价共识别1345项研究,54项进入全文审查,30项纳入最终分析;其中29项为队列研究,1项为随机对照试验。
- 最常报告的结局为用药至给药时间,在23项研究中与统计学显著获益相关。
- 较少研究报告死亡率等患者结局指标的显著差异。
- 仅8/30项研究评为低偏倚风险。
证据类型、等级与局限
- 证据类型:系统评价,纳入29项队列研究和1项随机对照试验;非随机研究采用纽卡斯尔-渥太华质量评估量表评估偏倚风险,随机试验采用修订版Cochrane偏倚风险工具。
- 局限:研究多为小型回顾性研究,不足以检测住院时长和死亡率等患者相关指标的差异;仅8/30项研究为低偏倚风险。
对床旁实践的改变
- 作者认为,系统评价结果支持药剂师在场和干预对复苏或医疗应急响应团队救治具有有益影响,可改善时间关键性药物启动时间、用药适宜性和指南依从性。
- 作者指出,未来研究应在急诊复苏场景中采用对照、前瞻性设计及稳健抽样方法,探讨药剂师的临床影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We sought to determine the impact of the presence of a pharmacist on medication and patient related outcomes during the emergency management of critically ill patients requiring resuscitation or medical emergency response team care in a hospital setting.
METHODS: We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search of databases from January 1995 to April 2023 was conducted to identify studies of contemporary pharmacist practice. Results were extracted and analysed for included studies, those evaluating the impact of the presence of a pharmacist on medication and patient related outcomes during the emergency management of critically ill hospitalised patients requiring resuscitation or medical emergency response team care. To determine risk of bias, the Newcastle-Ottowa Quality Assessment scale was used for non-randomised studies and the Revised Cochrane risk-of-bias tool for randomised trials.
RESULTS: Of 1345 studies identified, 54 were selected for full text review, and 30 were included in the final analysis. There were 29 cohort studies and one randomised controlled trial. The studies reported the impact of a pharmacist for a variety of patient presentations. The study team assigned each study to one of eight patient cohorts: acute stroke, cardiac arrest, rapid response calls, S-T segment elevation myocardial infarction, acute haemorrhage, major trauma resuscitation, sepsis and status epilepticus. The most frequently reported outcome, associated with a statistically significant benefit in 23 studies, was time to medication administration. Few studies reported a significant difference in patient outcome measures such as mortality. Only 8 of the 30 studies were assessed to have a low risk of bias.
CONCLUSIONS: The results of this systematic review provide support for a beneficial impact of a pharmacist presence and intervention during resuscitation or medical emergency response team care, with significant improvements in outcomes such as time to initiation of time-critical medications, medication appropriateness and guideline compliance. However, studies were predominantly small and retrospective and were not powered to detect differences in patient related measures such as length of stay and mortality. Future research should investigate the clinical impacts of the pharmacist in ED resuscitation settings in controlled, prospective studies with robust sampling methods.
参考来源
- Currey EM, Falconer N, Isoardi KZ, et al. Impact of pharmacists during in-hospital resuscitation or medical emergency response events: A systematic review. Am J Emerg Med. 2023. PMID: 37939522. doi:10.1016/j.ajem.2023.10.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。